Floatz logo

Mylotarg

Leukemia

M.D. Anderson Cancer Centerantibody_drug_conjugatePhase 2/3Dormant
CCC
50/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
65/ 100

Competitive context

125 Active assets in the Leukemia cohort.

Asset / SponsorPhaseRating
VINCRISTINE SULFATE
Inhye Ahn
Phase 3BB
ASPARAGINASE
Gruppo Italiano Malattie EMatologiche dell'Adulto
Phase 3BB
THIOGUANINE ANHYDROUS
Incyte Corporation
Phase 3BB
Idarubicine
Affiliated Hospital of Nantong University
Phase 3BB
Daunorubicin
Richard Stone, MD
Phase 3BB

View all 50 →

Same molecule, other indications

Mylotarg is also rated in:

Infusions, IntravenousDormant
BB
Indicative ·
66 / 100
View asset →
acute myeloid leukemiaDormant
B
Indicative ·
63 / 100
View asset →
myelodysplastic syndromeDormant
B
Indicative ·
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →